Recent acquisitions and our ongoing expansion efforts have laid the groundwork for a robust product pipeline. With an accelerated commitment to enhancing our capabilities with additional dosage forms and a focus on novel development and ANDA manufacturing, our pipeline is well-rounded and continues to grow.
Chartwell is aggressively seeking product acquisitions. If you have an asset that no longer fits your portfolio, please contact us to discuss how to maximize your opportunity.
Chartwell RX, LLC. distributes our full line of generic prescription products to the US commercial market, including wholesalers and distributors, retail pharmacies, managed healthcare and institutional accounts, and state and federal government facilities.
As a qualified small business manufacturing in the USA, Chartwell products are both Buy-American (BAA) and Trade Act Agreement (TAA) compliant. Our Congers, New York production facility has been a trusted producer for the Federal Emergency Stockpile, the Defense Logistic Agency, and numerous state emergency medical stockpiles.
We are well-prepared to sell to government entities
and supply state and federal contracts:
Trade Agreements Act (TAA)
Quick ramp-up of production
with available surge capacity
Focus on extended dating
program allows maximization
of investment of government
With a reputation for quality and reliability that spans over 20 years, Chartwell Pharmaceuticals is an experienced partner for your Contract Manufacturing needs. We value long-term relationships and strong partnerships as key to mutual success. We want to grow with our clients and serve their unmet needs.
Our global pharmaceutical expertise and entrepreneurial insight makes Chartwell uniquely suited to add significantly more value than a standard CDMO. We focus on creative business approaches that ensure real value for all parties. Chartwell is not just a service company, we’re a partner. We encourage our customers to consider our plant and professionals like your own. Your project will receive the same relentless attention to detail as we give to our label, and you can be proud to have products that say, “Made in America” and “Made at Chartwell!”
Recent acquisitions and our ongoing expansion efforts have laid the groundwork for a robust product pipeline. With an accelerated commitment to enhancing our capabilities with additional dose forms and a focus on novel development and ANDA manufacturing, our pipeline is well-rounded and continues to grow.
There’s plenty on the horizon for Chartwell Pharmaceuticals LLC:
Over 20 product launches anticipated in the coming 9 months
Pipeline of over 300 Orange Book listings
Capabilities for additional dosage forms currently being built out
Development of additional 505(b)(2) products underway